Brazil Acinetobacter Pneumonia Therapeutics Market Size & Outlook
Related Markets
Brazil acinetobacter pneumonia therapeutics market highlights
- The Brazil acinetobacter pneumonia therapeutics market generated a revenue of USD 7.2 million in 2024 and is expected to reach USD 10.8 million by 2030.
- The Brazil market is expected to grow at a CAGR of 7.2% from 2025 to 2030.
- In terms of segment, cephalosporins was the largest revenue generating drug class in 2024.
- Sulbactam is the most lucrative drug class segment registering the fastest growth during the forecast period.
Acinetobacter pneumonia therapeutics market data book summary
| Market revenue in 2024 | USD 7.2 million |
| Market revenue in 2030 | USD 10.8 million |
| Growth rate | 7.2% (CAGR from 2025 to 2030) |
| Largest segment | Cephalosporins |
| Fastest growing segment | Sulbactam |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cephalosporins , Fluoroquinolone , Glycylcycline , Carbapenem , β-Lactam antibiotics, Sulbactam, Aminoglycoside , Polymyxins, Tetracycline, Sulfonamide, Other Drug Classes |
| Key market players worldwide | Pfizer Inc, Merck & Co Inc, GlaxoSmithKline, AstraZeneca PLC, Novartis AG ADR, Johnson & Johnson, Sanofi SA, Bayer AG, Basilea Pharmaceutica Ltd |
Other key industry trends
- In terms of revenue, Brazil accounted for 2.2% of the global acinetobacter pneumonia therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil acinetobacter pneumonia therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Argentina is the fastest growing regional market in Latin America and is projected to reach USD 3.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Acinetobacter Pneumonia Therapeutics Market Scope
Acinetobacter Pneumonia Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Basilea Pharmaceutica Ltd | View profile | 147 | Hegenheimermattweg 167b, Allschwil, Switzerland, 4123 | https://www.basilea.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Brazil acinetobacter pneumonia therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to acinetobacter pneumonia therapeutics market will help companies and investors design strategic landscapes.
Cephalosporins was the largest segment with a revenue share of 13.89% in 2024. Horizon Databook has segmented the Brazil acinetobacter pneumonia therapeutics market based on cephalosporins , fluoroquinolone , glycylcycline , carbapenem , β-lactam antibiotics, sulbactam, aminoglycoside , polymyxins, tetracycline, sulfonamide, other drug classes covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Brazil acinetobacter pneumonia therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Brazil acinetobacter pneumonia therapeutics market databook
-
Our clientele includes a mix of acinetobacter pneumonia therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil acinetobacter pneumonia therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Brazil acinetobacter pneumonia therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Brazil acinetobacter pneumonia therapeutics market report size, by route of administration, 2018-2030 (US$M)
Brazil Acinetobacter Pneumonia Therapeutics Market Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
